Dr. Kardosh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-8534Fax+1 503-494-3257
Summary
- Dr. Adel Kardosh is an oncologist in Portland, OR. He received his medical degree from Keck School of Medicine of USC and completed Oncology fellowship at Stanford University. He has been in practice 6 years. He specializes in gastrointestinal cancer.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2017
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2011 - 2014
- Keck School of Medicine of the University of Southern CaliforniaClass of 2011
- Keck School of Medicine PhD, Molecular Biology and Immunology , 2002 - 2007
Certifications & Licensure
- CA State Medical License 2012 - 2026
- OR State Medical License 2018 - 2025
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 72 citationsDimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt’s l...Adel Kardosh, Weijun Wang, Jasim Uddin, Nicos A. Petasis, Florence M. Hofman
Cancer Biology & Therapy. 2005-04-05 - 72 citationsDifferential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.Adel Kardosh, Martina Blumenthal, Weijun Wang, Thomas C. Chen, Axel H. Schönthal
Cancer Biology & Therapy. 2004-01-01 - 12 citationsEffect of Time to Surgery of Colorectal Liver Metastases on Survival.Emerson Y. Chen, Skye C. Mayo, Thomas L. Sutton, Matthew R. Kearney, Adel Kardosh
Journal of Gastrointestinal Cancer. 2021-03-01
Press Mentions
- New Treatment Strategy Aims to Stop Rare Liver CancerJune 15th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: